Amneal Pharmaceuticals, Inc. Class A Common Stock Total Assets
Amneal Pharmaceuticals, Inc. Class A Common Stock total assets. Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) holds total assets worth $3.60 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Amneal Pharmaceuticals, Inc. Class A Com (AMRX) total market value for the company's overall valuation and market capitalisation.
Total Assets of Amneal Pharmaceuticals, Inc. Class A Common Stock (2014–2024)
Total assets of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2014 to 2024. This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's total assets have evolved over time, based on quarterly financial data. See AMRX stock price for real-time trading data and today's change.
Amneal Pharmaceuticals, Inc. Class A Common Stock - Asset Composition Analysis
Amneal Pharmaceuticals, Inc. Class A Common Stock Total Assets Breakdown (December 2024)
Amneal Pharmaceuticals, Inc. Class A Common Stock total assets breakdown as of December 2024. Amneal Pharmaceuticals, Inc. Class A Common Stock's total assets of $3.60 Billion consist of 45.4% current assets and 54.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.2% |
| Accounts Receivable | $808.56 Million | 23.1% |
| Inventory | $612.45 Million | 17.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $732.38 Million | 20.9% |
| Goodwill | $597.44 Million | 17.1% |
Asset Composition Trend (2014–2024)
This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Amneal Pharmaceuticals, Inc. Class A Com to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amneal Pharmaceuticals, Inc. Class A Common Stock's current assets represent 45.4% of total assets in 2024, an increase from 0.0% in 2014.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2024, up from 0.0% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 23.1% of total assets.
Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Total Assets
Key competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥9.94 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥13.81 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829
|
China | CN¥7.35 Billion |
Amneal Pharmaceuticals, Inc. Class A Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.13 | 1.38 | 2.29 |
| Quick Ratio | 1.42 | 0.84 | 1.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $976.37 Million | $418.08 Million | $874.64 Million |
Amneal Pharmaceuticals, Inc. Class A Common Stock - Advanced Valuation Insights
This section examines the relationship between Amneal Pharmaceuticals, Inc. Class A Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 86.10 |
| Latest Market Cap to Assets Ratio | 1.02 |
| Asset Growth Rate (YoY) | 0.8% |
| Total Assets | $3.50 Billion |
| Market Capitalization | $3.57 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Amneal Pharmaceuticals, Inc. Class A Common Stock's assets above their book value (1.02x), reflecting positive investor sentiment about the company's future prospects.
Positive Asset Growth: Amneal Pharmaceuticals, Inc. Class A Common Stock's assets grew by 0.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Amneal Pharmaceuticals, Inc. Class A Common Stock (2014–2024)
The table below shows the annual total assets of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.50 Billion | +0.83% |
| 2023-12-31 | $3.47 Billion | -8.60% |
| 2022-12-31 | $3.80 Billion | -3.56% |
| 2021-12-31 | $3.94 Billion | -1.66% |
| 2020-12-31 | $4.01 Billion | +9.28% |
| 2019-12-31 | $3.67 Billion | -15.78% |
| 2018-12-31 | $4.35 Billion | +224.37% |
| 2017-12-31 | $1.34 Billion | +10.10% |
| 2016-12-31 | $1.22 Billion | +20.19% |
| 2015-12-31 | $1.01 Billion | -47.25% |
| 2014-12-31 | $1.92 Billion | -- |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate an… Read more